REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

PHASE3CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

June 28, 2017

Primary Completion Date

July 8, 2020

Study Completion Date

April 6, 2021

Conditions
Cervical DysplasiaCervical High Grade Squamous Intraepithelial LesionHSIL
Interventions
BIOLOGICAL

VGX-3100

1 mL VGX-3100 will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.

BIOLOGICAL

Placebo

1 mL of Placebo will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.

DEVICE

Electroporation (EP)

Intramuscular injection followed by EP with the CELLECTRA™ 5PSP device.

Trial Locations (60)

157

Lynette Reynders Private Practice, Centurion

290

Kätilöopiston sairaala, Helsinki

3600

Ziekenhuis Oost-Limburg, Genk

6000

Perpetual Succour Hospital, Cebu

7000

Centre Hospitalier Universitaire Ambroise Paré, Mons

7925

University of Cape Town, Cape Town

8907

Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat

10032

Columbia University Medical Center, New York

10119

East Tallinn Central Hospital Womens Clinic, Tallinn

10700

Chulalongkorn University, Bangkok

Siriraj Hospital Mahidol University, Bangkok

11777

Suffolk Obstetrics and Gynecology, Port Jefferson

15083

Unidad de Ensayos Clinicos (UNIDEC) del Policlinico Universidad Nacional Mayor de San Marcos, Lima

15084

Liga Peruana De Lucha Contra El Cancer, Lima

20133

Istituto Nazionale Dei Tumori, Milan

20141

Istituto Europeo Di Oncologia, Milan

20246

Universitätsklinikum Hamburg Eppendorf, Hamburg

23502

Group For Women, Norfolk

23507

Eastern Virginia Medical School, Norfolk

27103

Lyndhurst Clinical Research, Winston-Salem

28040

Hospital Clinico San Carlos, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

29572

Magnolia Ob/Gyn Research Center, LLC, Myrtle Beach

29615

Greenville Pharmaceutical Research, Inc., Greenville

30912

Augusta University, Augusta

33409

Comprehensive Clinical Trials LLC, West Palm Beach

33461

Altus Research, Lake Worth

Salom and Tangir LLC, Miramar

33759

Women's Medical Research Group, Clearwater

37404

Chattanooga Medical Research Inc, Chattanooga

38104

Women's Physician Group, Memphis

44340

Nuevo Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara

45138

Elisabeth Krankenhaus Essen GmbH, Essen

48604

Saginaw Valley Medical Research Group LLC, Saginaw

51014

Tartu University Hospital, Tartu

68701

Meridian Clinical Research Norfolk, Norfolk

70072

Praetorian Pharmaceutical Research, LLC, Marrero

77074

UAG Innovation Women Research, LLC, Houston

85209

Mesa Obstetricians and Gynecologist, Mesa

85251

Women's Health Research, Scottsdale

85712

Visions Clinical Research-Tucson, Tucson

07103

New Jersey Medical School, Newark

S2000PBB

Instituto de Ginecología, Rosario

C1181ACH

Hospital Italiano de Buenos Aires, Buenos Aires

B1704ETD

DIM Clínica Privada, Ramos Mejía

EE-80010

Pärnu Hospital, Pärnu

FI-70110

Lääkäriasema Cantti Oy, Kuopio

00168

Fondazione Policlinico Universitario A Gemelli, Rome

LT- 08661

Vilnius University Hospital Santaros Klinikos, Vilnius

LT-01117

Vilnius District Central Outpatient Clinic, Vilnius

20-880

Niepubliczny Zakład Opieki Zdrowotnej Profimed, Lublin

Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie, Lublin

40-611

Centrum Medyczne Angelius Provita, Katowice

3000-075

Centro Hospitalar E Universitário de Coimbra EPE, Coimbra

1649-035

Centro Hospitalar de Lisboa Norte, EPE - Hospital de Santa Maria, Lisbon

00935

Puerto Rico Translational Research Center (PRTRC), Rio Piedras

018 41

MCM GYNPED, s.r.o., Dubnica nad Váhom

036 59

Univerzitna nemocnica Martin, Martin

AB25 7ZD

Aberdeen Royal Infirmary - PPDS, Aberdeen

W2 1NY

St Marys Hospital, London

Sponsors
All Listed Sponsors
lead

Inovio Pharmaceuticals

INDUSTRY

NCT03185013 - REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) | Biotech Hunter | Biotech Hunter